Core Viewpoint - Analysts expect Regeneron to report quarterly earnings of $8.76 per share, reflecting a year-over-year decline of 8.3%, with revenues projected at $3.25 billion, an increase of 3.3% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 6.1% lower in the last 30 days, indicating a collective reevaluation by analysts [1][2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [2]. Revenue Projections - Analysts predict 'Revenues- Other Revenue' to reach $132.13 million, a 13% increase year-over-year [4]. - 'Revenues- Net product sales' are expected to be $1.62 billion, indicating a decline of 8.2% from the previous year [4]. - 'Total Bayer collaboration revenue' is projected at $374.73 million, reflecting a 5.3% year-over-year increase [4]. - The consensus estimate for 'Revenues- Collaboration' stands at $1.49 billion, a 17.9% increase from the year-ago quarter [5]. Product-Specific Revenue Estimates - 'Revenues- Praluent (alirocumab)- US' are expected to be $57.71 million, down 17.6% year-over-year [5]. - 'Revenues- Eylea (Aflibercept)- US' are projected at $1.19 billion, indicating a decline of 15.2% [5]. - 'Revenues- Evkeeza- US' are estimated at $32.40 million, a 35% increase year-over-year [6]. - 'Revenues- Libtayo- ROW' are expected to reach $127.95 million, reflecting a 22.2% increase [6]. - 'Revenues- Libtayo- US' are projected at $214.99 million, indicating a 35% year-over-year increase [6]. - 'Revenues- Dupixent (dupilumab)- ROW' are expected to be $1.08 billion, a 25.7% increase [7]. - 'Revenues- Kevzara (sarilumab)- ROW' are projected at $41.91 million, down 5% year-over-year [7]. - 'Revenues- Kevzara (sarilumab)- US' are expected to reach $52.50 million, indicating a 5% increase [7]. Stock Performance - Over the past month, Regeneron shares have declined by 8.2%, compared to a 5.1% decline in the Zacks S&P 500 composite [8]. - Based on its Zacks Rank 4 (Sell), Regeneron is expected to underperform the overall market in the upcoming period [8].

Wall Street analysts expect Associated Banc-Corp (ASB) to post quarterly earnings of $0.57 per share in its upcoming report, which indicates a year-over-year increase of 9.6%. Revenues are expected to be $350.71 million, up 7.4% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is cru ...

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short- term price performance of a stock. The upcoming report from COPT Defense (CDP) is expected to reveal quarterly earnings of $0.65 per share, indicating an increase of 4.8% compar ...

Wall Street analysts forecast that Brunswick (BC) will report quarterly earnings of $0.25 per share in its upcoming release, pointing to a year-over-year decline of 81.5%. It is anticipated that revenues will amount to $1.14 billion, exhibiting a decline of 16.6% compared to the year-ago quarter. The current level reflects a downward revision of 0.6% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their ...

Core Viewpoint - Analysts project AbbVie (ABBV) will report quarterly earnings of $2.40 per share, a 3.9% increase year over year, with revenues expected to reach $12.91 billion, reflecting a 4.8% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.8% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial for predicting investor actions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Net Revenue- Botox Cosmetic- Total' at $576.62 million, down 8.9% year over year [5]. - 'Net Revenue- Imbruvica' is projected to be $676.15 million, reflecting a decrease of 19.3% from the prior-year quarter [5]. - 'Net Revenue- Eye Care- Total' is expected to be $531.41 million, indicating a slight decline of 1.2% [5]. - 'Net Revenue- Juvederm Collection- Total' is forecasted at $253.59 million, down 14.6% from the year-ago quarter [6]. - 'Net Revenue- Creon- US' is estimated at $267.00 million, a decrease of 6.3% year over year [6]. - 'Net Revenue- Rinvoq- International' is projected to reach $504.96 million, an increase of 37.2% from the prior-year quarter [6]. - 'Net Revenue- Rinvoq- US' is expected to be $1.09 billion, reflecting a significant increase of 50.2% year over year [7]. - 'Net Revenue- Humira- International' is estimated at $422.30 million, down 15.4% from the prior-year quarter [7]. - 'Net Revenue- Humira- US' is projected at $898.84 million, indicating a substantial decline of 49.3% year over year [7]. - 'Net Revenue- Immunology- Skyrizi- International' is expected to be $507.22 million, up 44.1% year over year [8]. - 'Net Revenue- Immunology- Skyrizi- US' is projected at $2.69 billion, reflecting a 62.3% increase year over year [8]. - The consensus estimate for 'Geographic Revenues- International' stands at $3.42 billion, indicating a 4.5% increase from the prior-year quarter [9]. Stock Performance - Over the past month, AbbVie shares have returned -18.7%, compared to the Zacks S&P 500 composite's -8.9% change [9].

It is projected by analysts that the 'Average Daily Production Volumes - Total oil equivalent' will reach 196,169.00 millions of barrels of oil equivalent. Compared to the present estimate, the company reported 149760 millions of barrels of oil equivalent in the same quarter last year. The combined assessment of analysts suggests that 'Average Daily Production Volumes - Oil' will likely reach 114,841.60 BBL/D. The estimate is in contrast to the year-ago figure of 84,777 BBL/D. Over the last 30 days, there h ...

Core Viewpoint - Wall Street analysts anticipate a slight decline in Merit Medical's quarterly earnings per share, while revenues are expected to show growth compared to the previous year [1]. Earnings Estimates - Analysts expect Merit Medical (MMSI) to report earnings of $0.75 per share, reflecting a year-over-year decline of 2.6% [1]. - Revenue is projected to be $352.33 million, indicating an increase of 8.9% from the same quarter last year [1]. - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by covering analysts [1][2]. Revenue Projections - Revenue from 'Cardiovascular- Peripheral Intervention' is estimated to reach $141.95 million, a year-over-year increase of 5.4% [4]. - 'Cardiovascular- Cardiac Intervention' revenue is expected to be $98.79 million, reflecting an 8.9% increase year over year [4]. - 'Endoscopy' revenue is projected at $17.89 million, showing a significant year-over-year increase of 76.5% [5]. - 'Cardiovascular- OEM' revenue is expected to be $43.84 million, indicating an 11.6% increase from the previous year [5]. - Total 'Cardiovascular' revenue is projected to reach $334.45 million, reflecting a 6.7% year-over-year change [5]. Geographic Sales Estimates - 'Geographic Sales- United States' is estimated at $208.66 million, suggesting a year-over-year increase of 12.1% [6]. - 'Geographic Sales- International' is projected to be $143.33 million, indicating a 4.3% increase year over year [6]. Stock Performance - Over the past month, Merit Medical shares have decreased by 10.6%, compared to a 5.6% decline in the Zacks S&P 500 composite [7]. - Currently, MMSI holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [7].

Core Viewpoint - Knight-Swift Transportation Holdings (KNX) is expected to report quarterly earnings of $0.25 per share, reflecting a year-over-year increase of 108.3%, while revenues are anticipated to decline by 0.9% to $1.81 billion [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 12.5%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue and Key Metrics - Analysts estimate 'Revenue, excluding truckload and LTL fuel surcharge' at $1.60 billion, a year-over-year change of -0.8% [5]. - The 'Truckload and LTL fuel surcharge' is projected to reach $185.70 million, down 11.4% from the previous year [5]. - 'Operating revenue- LTL' is expected to be $337.40 million, reflecting a year-over-year increase of 19.6% [6]. - The consensus for 'Revenue, excluding fuel surcharge and intersegment transactions- Truckload Segment' is $1.05 billion, indicating a decline of 3.7% year-over-year [6]. Operating Ratios - The average 'Operating Ratio' is projected at 95.7%, improving from 98.9% in the same quarter last year [6]. - The 'Adjusted Operating Ratio' is expected to be 94.7%, compared to 96.8% in the previous year [7]. - For 'Adjusted Operating Ratio - Truckload', the estimate is 95.3%, down from 97.3% year-over-year [7]. - The 'Adjusted Operating Ratio - LTL' is projected at 93.4%, compared to 90% in the same quarter last year [8]. - The 'Adjusted Operating Ratio - Logistics' is expected to be 93.7%, down from 97.1% in the previous year [8]. Operational Metrics - The consensus for 'Average tractors - Truckload' is 21,818, down from 23,314 year-over-year [9]. - 'Load count - Intermodal' is expected to reach 38,120, an increase from 33,647 in the previous year [9]. - The 'Average revenue per load - Intermodal' is projected at $2,684.32, compared to $2,615 last year [9]. Market Performance - Knight-Swift shares have returned -11.3% over the past month, underperforming the Zacks S&P 500 composite, which declined by -5.6% [9].

Core Viewpoint - Analysts forecast Discover (DFS) will report quarterly earnings of $3.32 per share, reflecting a year-over-year increase of 201.8%, with revenues expected to be $4.21 billion, showing no change from the previous year [1] Earnings Estimates - Over the last 30 days, there has been a downward revision of 1.4% in the consensus EPS estimate for the quarter, indicating a collective reconsideration by analysts [2] - Changes in earnings estimates are crucial for predicting potential investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [3] Key Metrics Forecast - Analysts predict 'Net Interest Margin' will reach 11.7%, up from 11% year-over-year [5] - 'Operating Efficiency' is estimated at 39.7%, down from 54.9% year-over-year [5] - 'Credit Card Loans - Discover Card Sales Volume' is expected to be $49.75 billion, compared to $50.14 billion in the same quarter last year [5] - 'Net Principal Charge-off Rate' is projected at 5.1%, up from 4.9% year-over-year [6] - 'Credit Card Loans - Total Discover Card Volume' is expected to be $52.52 billion, down from $53.24 billion year-over-year [6] - 'Network Volume - Total Payment Services' is forecasted to reach $105.02 billion, compared to $100.32 billion in the same quarter last year [7] - 'Tier 1 Risk Based Capital Ratio' is expected to be 15.4%, up from 11.7% year-over-year [7] - 'Transactions Processed on Networks - Total' is estimated at $3.43 billion, compared to $3.20 billion last year [8] - 'Network Volume - Diners Club International' is forecasted to reach $10.83 billion, up from $10.18 billion year-over-year [8] - 'Network Volume - Network Partners' is estimated at $9.45 billion, down from $11.07 billion year-over-year [9] - 'Network Volume - PULSE Network' is expected to reach $85.72 billion, up from $79.07 billion year-over-year [9] - 'Transactions Processed on Networks - Discover Network' is projected at $909.38 million, compared to $883 million last year [10] Stock Performance - Shares of Discover have shown returns of -3.2% over the past month, compared to the Zacks S&P 500 composite's -5.6% change, with a Zacks Rank 3 (Hold) indicating expected performance in line with the overall market [11]

Core Insights - Xcel Energy (XEL) is expected to report quarterly earnings of $0.96 per share, a 9.1% increase year-over-year, with revenues projected at $3.93 billion, reflecting a 7.8% increase compared to the same period last year [1] Earnings Estimates - There has been a downward revision of 5.6% in the consensus EPS estimate over the last 30 days, indicating analysts' reassessment of their initial forecasts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - The consensus estimate for 'Operating revenues- Electric and natural gas' is $3.91 billion, representing a 7.9% increase from the previous year [5] - 'Operating revenues- Other' is expected to be -$60.80 million, indicating a significant decline of 364.3% year-over-year [5] - 'Operating revenues- Natural Gas' is forecasted to reach $921.31 million, suggesting a slight decrease of 2.1% year-over-year [5] - Analysts predict 'Operating revenues- Electric' will likely be $2.99 billion, reflecting an 11.4% increase year-over-year [6] Market Performance - Xcel shares have returned +1.5% over the past month, contrasting with the Zacks S&P 500 composite's -5.6% change [6] - Xcel holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market in the near future [6]